This is a routine new-hire equity grant with negligible dilution. No trading action warranted; monitor for any future updates on clinical or commercial progress for Amtagvi.
Price Chart
Executive Summary
Iovance Biotherapeutics granted inducement stock options covering 140,860 shares to 27 new non-executive employees under its 2021 Inducement Plan, with an exercise price of $3.91 per share and a three-year vesting schedule. This is a routine equity grant to attract new hires and has no material impact on the company's financials or operations.
Key Facts
- Granted inducement stock options for 140,860 shares to 27 new non-executive employees.
- Exercise price set at $3.91, the closing price on June 18, 2026.
- Options vest over three years: one-third on first anniversary, remainder in quarterly installments.
- Granted under Iovance's Amended and Restated 2021 Inducement Plan per Nasdaq Listing Rule 5635(c)(4).
Financial Impact
140,860 shares represent approximately 0.1% of outstanding shares (based on ~140M shares outstanding); no material financial impact.
Risk Factors
- Minimal dilution from option exercises if stock price appreciates.
- No impact on near-term revenue or pipeline catalysts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3314899 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 5w ago | Press Release | $8.06 $10.64 | ▲ +32.01% | ▲ +30.70% | $14.24 (+76.67%) |
Aug 6, 2026 8w ago | 8-K | $6.34 $8.79 | ▲ +38.64% | ▲ +39.04% | $14.24 (+124.61%) |
Aug 6, 2026 8w ago | 8-K | $6.21 $8.70 | ▲ +40.10% | ▲ +39.50% | $14.24 (+129.31%) |
Jul 16, 2026 11w ago | Court Ruling | $4.66 $6.52 | ▼ −39.91% | ▼ −36.30% | $14.24 (−205.58%) |
Jul 2, 2026 13w ago | 8-K | $4.31 $4.69 | ▲ +8.82% | ▲ +9.23% | $14.24 (+230.39%) |
Jun 19, 2026 14w ago | Press Release | $4.06 $5.00 | ▲ +23.15% | ▲ +23.30% | $14.24 (+250.74%) |
Jun 18, 2026 15w ago | S-3ASR | $4.06 $5.00 | ▲ +23.15% | ▲ +23.30% | $14.24 (+250.74%) |
Jun 10, 2026 16w ago | 8-K | $3.96 $4.37 | ▲ +10.35% | ▲ +8.46% | $14.24 (+259.60%) |
May 22, 2026 18w ago | Press Release | $4.10 $4.34 | ▲ +5.87% | ▲ +7.81% | $14.24 (+247.32%) |
Apr 28, 2026 22w ago | DEFA14A | $3.31 $4.30 | ▲ +29.91% | ▲ +23.86% | $14.24 (+330.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access